(Total Views: 597)
Posted On: 06/04/2020 9:32:07 AM
Post# of 145873
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: Coocooburra #36585
Lovely compilation of info, CCB. The take home message is that mild/moderate can turn awful almost overnight. Seeing all these papers bearing the same message forcefully pounds in the message that things turn bad in a hurry when the immune response goes haywire. The point of leronlimab is to short-circuit that haywire response, and prevent progression to severe/critical. And there's good reason to think it works.
For the trials, the questions now are how often these events happen (5%, 10%, 20%?), will leronlimab prevent disease progression (seems like it should), and what will the final enrollment number be? If it's 5-10% and n = 50, statistical significance might not be there. If it's 10-20% and n = 75, we could very well see NP's beautiful results that will "shock the world".
For the trials, the questions now are how often these events happen (5%, 10%, 20%?), will leronlimab prevent disease progression (seems like it should), and what will the final enrollment number be? If it's 5-10% and n = 50, statistical significance might not be there. If it's 10-20% and n = 75, we could very well see NP's beautiful results that will "shock the world".
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)